CNBX Pharmaceuticals Inc. (CNBX) Form 10-Q — Jun 24, 2026

CNBX Pharmaceuticals reported no revenue for the nine months ended May 31, 2026, recording a net loss of $311,982. The company's cash position dwindled to $9,487 from $15,111 at the end of the prior fiscal year. Management explicitly raised substantial doubt about the Company's ability to continue as a going concern, noting that expected minimum expenses of $1,000,000 over the next twelve months far exceed current resources. The company stated it must raise additional capital through borrowing, equity issuance, or strategic arrangements to survive.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.